Impact of quick pneumonia panel on antibiotic choices for hospitalized adults
Official title: A Randomized Multicenter Clinical Trial Comparing BIOFIRE® FILMARRAY® Pneumonia (PN) Panels Versus Routine Diagnostic Methods in Desirability of Outcome Ranking for the Management of Antimicrobial Therapy (DOOR MAT) in Hospitalized Patients With Lower Respiratory Tract Infections.
Run by Hospital de Clinicas de Porto Alegre · NCT07585604 · Data updated 2026-11-12
This study tests whether a rapid pneumonia panel can help doctors choose better antibiotics sooner for adults with hospital‑acquired or ventilator‑associated pneumonia.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 150 (estimated) |
| Sponsor | Hospital de Clinicas de Porto Alegre Academic / other |
| Locations | 1 site (Porto Alegre, Rio Grande do Sul) |
| Status | Recruiting |
| Started | May 20, 2026 |
| Main results expected | May 2, 2027 |
| Study ends | June 2, 2027 |
| Registry record updated | September 17, 2026 |
| Trial ID | NCT07585604 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults (18+) with hospital‑acquired pneumonia or clinically relevant tracheobronchitis requiring antimicrobial therapy, without recent qualifying respiratory cultures, who can consent.
✕Probably not a fit
Patients with inadequate respiratory samples, incarcerated individuals, or pregnant women may not benefit from the approach.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
The trial evaluates a multiplex PCR-based pneumonia panel (BioFire FilmArray Pneumonia Panel) versus standard diagnostics to see if it improves antimicrobial decisions. It focuses on adults with hospital‑acquired pneumonia or clinically relevant tracheobronchitis who require treatment. Results are expected to show whether faster pathogen and resistance information leads to more appropriate antibiotic use and potentially better outcomes. The study is conducted at a single center in Porto Alegre, Brazil, with collaboration from BioMérieux. Patients will be enrolled if they have not had a recent respiratory culture meeting inclusion criteria and consent to participate.
Why it matters
Potential benefit: If successful, patients may receive antibiotics that are better suited to the infection sooner, potentially reducing unnecessary broad‑spectrum use.
How similar studies have gone: Previous research in other settings suggests rapid diagnostics can improve antimicrobial decisions, but results can vary by setting and panel used.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Age ≥18 years. * Clinical diagnosis of hospital-acquired pneumonia or clinically relevant tracheobronchitis requiring antimicrobial treatment, with or without mechanical ventilation. * No respiratory cultures collected in the last 72 hours (except for the culture that will potentially be evaluated in the study-trigger for inclusion). * Agreement from the patient or legal representative to sign the Informed Consent Form (ICF). Exclusion Criteria: * Inadequate respiratory samples according to laboratory cutoffs for squamous epithelial cells and polymorphonuclear leukocytes (sputum or endotracheal aspirate). * Incarcerated populations. * Pregnant women.
Where it's running
-
Hospital de Clínicas de Porto Alegre
Porto Alegre, Rio Grande do Sul, Brazil Recruiting
Study contacts
- Principal investigator: Maria Helena Rigatto, MD, PhD — Hospital de Clinicas de Porto Alegre
- Study coordinator: Maria Helena Rigatto, MD, PhD
- Email: mrigatto@hcpa.edu.br
- Phone: +55 51 33597759
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
MP101 plus antibiotics in adults with acute Pseudomonas pneumonia
This study tests whether a single IV dose of MP101, added to standard antibiotics, is safe and tolerable in adults with acute Pseudomonas aeruginosa pneumonia.
-
Urine Pneumococcal Antigen Test in Children with Pneumonia
This study tests a non-invasive urine test to see if it can detect pneumococcal pneumonia and identify serotypes in children under five in Malawi.
-
Jet versus vibrating mesh inhalation of polymyxin B for ventilated patients with carbapenem‑resistant Gram‑negative pneumonia
This trial tests whether jet nebulizers or vibrating mesh nebulizers deliver inhaled polymyxin B more effectively for mechanically ventilated patients with carbapenem‑resistant Gram‑negative pneumonia.
-
Improving treatment of pneumonia in children using lung ultrasound
This study is testing if using lung ultrasound can help doctors treat pneumonia in kids better and reduce the need for unnecessary antibiotics.
-
Nebulized amikacin for VA-ECMO–associated pneumonia in adults
We’re testing whether giving amikacin as a nebulized inhaled medicine helps clear gram-negative pneumonia in adults on VA-ECMO who are also on mechanical ventilation.
-
Reducing unnecessary MRSA treatment in pneumonia patients using nasal screening
This study is testing if using a nasal test for MRSA can help doctors quickly reduce unnecessary antibiotic treatment in pneumonia patients to improve their recovery and lower side effects.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.